Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease (Q38503919)

3 September 2017

1 reference

title

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease (English)

1 reference

3 September 2017

Rackley CE

1 reference

3 September 2017

publication date

1 September 1996

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

683-689

1 reference

Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

Clinical outcome 5 years after attempted percutaneous transluminal coronary angioplasty in 427 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Cholesterol and lipoproteins: beyond atherogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

The oxidative modification of low density lipoprotein by human lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190903

7 January 2021

Identifiers

DOI

10.1002/CLC.4960190903

1 reference

3 September 2017

1 reference